The Types dimension classifies Cytogenetic Arrays into three technology families: array comparative genomic hybridization (aCGH), single‑nucleotide‑polymorphism (SNP) arrays, and combined aCGH‑SNP platforms. aCGH arrays, representing roughly 40 % of unit shipments, provide quantitative detection of copy‑number gains and losses across the genome and are preferred for high‑throughput clinical screens where single‑base resolution is not required. SNP arrays, contributing about 35 % of market volume, add genotype information that enables loss‑of‑heterozygosity and uniparental disomy analysis, thereby extending utility in oncology and rare‑disease diagnostics. Combined aCGH‑SNP platforms, accounting for the remaining 25 %, integrate the strengths of both approaches, delivering simultaneous copy‑number and allelic imbalance data, which is increasingly demanded in comprehensive genomic profiling. The proportional distribution of these types directly influences manufacturing capacity, R&D investment, and pricing structures within the Cytogenetic Arrays market taxonomy. As clinical guidelines evolve to favor integrated genomic insight, the combined segment is projected to capture a larger share of future growth.